Genolution

Genolution FCF/Debt

The Free Cash Flow to Debt Ratio of Genolution (225220.KQ) as of Nov 11, 2026 is -56.57 %. In the previous year, Free Cash Flow to Debt Ratio was -33.31 % — a change of 69.82% (lower).

FCF/Debt

-56.57 %

YoY

69.82%

Last updated:

Free Cash Flow to Debt Ratio of Genolution is 2024 -56.57 % . Free Cash Flow to Debt Ratio of Genolution was 2023 -33.31 % . It decreases by 69.82% lower compared to the previous year.

The Genolution FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2018
-168.98 KRW
Jan 1, 2019
-90.80 KRW
Jan 1, 2020
560.98 KRW
Jan 1, 2022
-59.72 KRW
Jan 1, 2023
-33.31 KRW
Jan 1, 2024
-56.57 KRW
The Genolution FCF/Debt history
YEARFCF/DebtYoY
-56.57 %+69.82%
-33.31 %-44.22%
-59.72 %-110.65%
560.98 %-717.79%
-90.80 %-46.26%
-168.98 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genolution Stock analysis

What does Genolution do? Genolution Inc develops automated nucleic acid extraction devices, nucleic acid extraction reagents, and molecular diagnostic products. The company also offers ribonucleic acid interference services. Its products are distributed domestically and internationally, serving customers in the biotechnology and healthcare sectors. The firm generates revenue through the sale of these products and services to research institutions, laboratories, and healthcare providers. The company's core offerings include nucleic acid extractors, reagents, and diagnostic products, which are used in molecular biology and medical diagnostics. Genolution Inc targets biotech firms, hospitals, and research facilities as key buyers of its technology. Its domestic market presence complements its international distribution channels. Genolution Inc's business model relies on selling its automated extraction devices and reagents to customers requiring efficient nucleic acid processing solutions. The company's molecular diagnostic products cater to healthcare applications, while its ribonucleic acid interference services support advanced research needs. Revenue streams are derived from both product sales and service contracts within the biotechnology industry. Genolution is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genolution stock

Free Cash Flow to Debt Ratio of Genolution is -56.57 % in 2024.

Free Cash Flow to Debt Ratio of Genolution changed from -33.31 % to -56.57 %, representing a 69.82% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Genolution since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Genolution with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Genolution

All Key Metrics — Genolution